Evidence map›Paper›PMID 25612848›Full record

ArticleNature communications2015

DNA sequencing using polymerase substrate-binding kinetics.

Michael John Robert Previte, Chunhong Zhou, Matthew Kellinger, Rigo Pantoja, Cheng-Yao Chen, Jin Shi, BeiBei Wang, Amirali Kia, Sergey Etchin, John Vieceli and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael John Robert PreviteProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Chunhong ZhouEngineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Matthew KellingerProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Rigo PantojaProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Cheng-Yao ChenProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Jin ShiProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
BeiBei WangProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Amirali KiaProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Sergey EtchinEngineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
John VieceliBioinformatics, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Ali NikoomanzarProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Erin BomatiProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Christian GloecknerProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Mostafa RonaghiProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.
Molly Min HeProtein Engineering, Illumina Inc., 5200 Research Place, San Diego, California 92122, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation sequencing (NGS) has transformed genomic research by decreasing the cost of sequencing. However, whole-genome sequencing is still costly and complex for diagnostics purposes. In the clinical space, targeted sequencing has the advantage of allowing researchers to focus on specific genes of interest. Routine clinical use of targeted NGS mandates inexpensive instruments, fast turnaround time and an integrated and robust workflow. Here we demonstrate a version of the Sequencing by Synthesis (SBS) chemistry that potentially can become a preferred targeted sequencing method in the clinical space. This sequencing chemistry uses natural nucleotides and is based on real-time recording of the differential polymerase/DNA-binding kinetics in the presence of correct or mismatch nucleotides. This ensemble SBS chemistry has been implemented on an existing Illumina sequencing platform with integrated cluster amplification. We discuss the advantages of this sequencing chemistry for targeted sequencing as well as its limitations for other applications.

Indexed as

Sequence Analysis, DNABacteriophage phi X 174Base Pair MismatchBase SequenceDNADNA-Directed DNA PolymeraseEquipment DesignGenome, ViralGenomicsHigh-Throughput Nucleotide SequencingKineticsMolecular Sequence DataNucleotidesPolymersDNADNA-Directed DNA PolymeraseNucleotidesPolymers

Identifiers

PMID25612848
PMCPMC4354037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.